1.
Quel pourrait être le futur de la prise en charge de l'anémie dans l'insuffisance rénale chronique ?
Nephrol Ther
; 13(6S): 6S7-6S10, 2017 Jun.
Article
in French
| MEDLINE
| ID: mdl-29463398
ABSTRACT
Erythropoietin (EPO) plays an essential role in the regulation of erythropoiesis. Its production is under the control of the Hypoxia Inducible Factor (HIF) protein whose stability varies according to the oxygen level. During chronic renal failure, EPO deficiency is the main cause of anemia, but other factors such as iron deficiency and inflammatory syndrome are also involved. More recently, it is hypothesized that other factors such an excess of GDF-11 production may be also involved. Thus, beside Epo treatment HIF and GDF-11 are potentially new therapeutic targets in anemia of chronic kidney disease.